AIA Group Ltd Boosts Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

AIA Group Ltd lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 32.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,448 shares of the medical research company’s stock after acquiring an additional 3,568 shares during the quarter. AIA Group Ltd’s holdings in Thermo Fisher Scientific were worth $7,669,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of TMO. Coppell Advisory Solutions LLC acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth about $33,000. Live Oak Investment Partners acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth about $36,000. Tyler Stone Wealth Management acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth about $37,000. Raleigh Capital Management Inc. raised its holdings in Thermo Fisher Scientific by 49.1% in the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock valued at $41,000 after acquiring an additional 27 shares during the last quarter. Finally, Cedar Mountain Advisors LLC raised its holdings in Thermo Fisher Scientific by 107.0% in the 4th quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 46 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the sale, the director now directly owns 1,207 shares in the company, valued at approximately $660,192.79. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the sale, the director now directly owns 1,207 shares in the company, valued at approximately $660,192.79. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the sale, the senior vice president now owns 12,901 shares in the company, valued at $7,250,362. The disclosure for this sale can be found here. In the last three months, insiders have sold 50,277 shares of company stock worth $28,513,384. 0.32% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Down 1.1 %

TMO stock traded down $5.94 during midday trading on Thursday, hitting $541.31. The company’s stock had a trading volume of 1,548,272 shares, compared to its average volume of 1,539,883. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $603.82. The firm has a market capitalization of $206.62 billion, a P/E ratio of 34.94, a PEG ratio of 2.33 and a beta of 0.80. The firm has a 50-day simple moving average of $571.57 and a 200-day simple moving average of $527.01.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, beating the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The company had revenue of $10.89 billion during the quarter, compared to analysts’ expectations of $10.73 billion. During the same quarter last year, the company posted $5.40 EPS. The firm’s revenue was down 4.9% compared to the same quarter last year. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.29%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.10%.

Wall Street Analyst Weigh In

A number of analysts have commented on TMO shares. Royal Bank of Canada increased their price objective on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 price target for the company. Evercore ISI raised their price target on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. The Goldman Sachs Group raised their price target on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Finally, HSBC raised their price target on shares of Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock a “buy” rating in a report on Wednesday. Five research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $604.69.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.